Ability Biotherapeutics Moves to Inspire Bio Innovations in Montreal, Pioneering the New Generation of Targeted Antibodies
Ability Biotherapeutics, a Quebec-based leader in antibody therapeutics, is proud to announce its new location at Inspire Bio Innovations. The company will occupy the 6th floor of Phase 2 in the transformative redevelopment of the former Montreal Chest Institute, marking a significant step in its growth within Montreal's thriving life sciences ecosystem.
The project's first phase is scheduled for completion this summer, with the second phase, including Ability's new space, expected to wrap up by the end of 2026. Ability Biotherapeutics is pioneering a new generation of targeted antibody therapies for cancer and autoimmune diseases, powered by its proprietary generative AI-based AbiLeap™ platform. Ability is advancing multiple drug discovery programs, with three lead programs now entering optimization and development as it prepares for preclinical studies. Taking advantage of Inspire Bio Innovations' dynamic environment, Ability plans to complete preclinical studies to demonstrate the effectiveness of its therapeutic products and to begin large-scale production in preparation for the first human clinical trials. These steps are expected to enable the company to triple its number of employees by 2028.
Since its unveiling less than two years ago, the Inspire project has sparked genuine enthusiasm within the life sciences ecosystem. Initially hosting the headquarters of Cellcarta, it has since brought together various Montreal universities and the Montreal Clinical Research Institute (IRCM). The project gained international recognition by being awarded the title of Future Office Project of the Year at the prestigious World Architecture Festival (WAF). This life sciences hub is already attracting a community of forward-thinking researchers and entrepreneurs focused on innovation, and continues to welcome companies from around the world seeking to thrive in its dynamic environment.
Located in the heart of downtown Montreal, Inspire Bio Innovations offers an ideal location with easy access via public and active transportation and proximity to major highways. This life sciences innovation hub is strategically located near a vibrant community of research centres and top-tier researchers, including MILA, CR-CHUM, CR-CUSUM, IRCM, and IRIC. This proximity will significantly enhance interactions and knowledge sharing. Additionally, being close to major hospitals like CHUM and MUHC will streamline the execution of local clinical studies. These factors make Inspire Bio Innovations highly attractive for retaining current talent and recruiting global experts.
Quotes
'We are excited to pursue our activities within Inspire Bio Innovations, a cutting-edge hub that fosters exchanges and interactions with top-tier researchers and innovative entrepreneurs. The collaborative environment created by Jadco is ideal for advancing the development of therapies with the potential to transform the treatment of patients with cancer or autoimmune diseases, both in Québec and globally.'—Patrick Tremblay, Ph.D., Chief Operating Officer at Ability Biotherapeutics.
'We firmly believe that Inspire Bio Innovations is the ideal hub for nurturing the next generation of researchers and innovators who will propel the entire life sciences ecosystem forward. Montreal possesses all the attributes necessary to strengthen its role as one of the most dynamic and promising international centres in this field. This new space, dedicated to innovation and precision medicine, will unite talented teams whose work will continue this tradition while facilitating the commercialization of discoveries.'—Normand Rivard, Managing Partner, Life Sciences and Innovation, Jadco Group.
'Ability Biotherapeutics' addition to the Inspire Bio Innovations scientific hub once again demonstrates the excellence of this innovation centre dedicated to scientific research. This new partnership strengthens the project's leading role in biotechnology. We are delighted to see this promising collaboration take shape in Plateau-Mont-Royal.'—Luc Rabouin, Leader of Projet Montréal.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250429167085/en/
CONTACT: Information and interviews:
Stéphanie Bilodeau
Communication Advisor
Ability Biotherapeutics
[email protected]
KEYWORD: NORTH AMERICA CANADA
INDUSTRY KEYWORD: ONCOLOGY HEALTH TECHNOLOGY HEALTH TECHNOLOGY ARTIFICIAL INTELLIGENCE BIOTECHNOLOGY
SOURCE: Ability Biotherapeutics
Copyright Business Wire 2025.
PUB: 04/29/2025 07:45 AM/DISC: 04/29/2025 07:44 AM
http://www.businesswire.com/news/home/20250429167085/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 minutes ago
- Business Wire
Family Health Services of Darke County and AndHealth Celebrate Ribbon Cutting and Launch of Retail + Specialty Pharmacy at Expanded Greenville Location
GREENVILLE, Ohio--(BUSINESS WIRE)--Family Health Services of Darke County and AndHealth will celebrate the opening of Family Health Services' retail and specialty pharmacy on Thursday, August 7 th at 4:00 PM. The ribbon cutting will take place at Family Health Services' newly expanded Greenville facility, located at 5735 Meeker Road, and will be followed by an open house from 5:00 – 8:00 PM featuring light refreshments, family-friendly activities, and tours of the renovated space. "With this expansion, we're not just adding services, we're closing care gaps and removing barriers to health for our neighbors.' This milestone marks a major step forward in Family Health Services' mission of Building Healthy Lives Together. This expansion adds 44,000 square feet of clinical space, modernizes the patient experience, and introduces expanded pharmacy services, including the launch of Darke County's only specialty pharmacy. These enhancements will significantly improve access for patients managing chronic and complex conditions, particularly those impacted by long-standing pharmacy shortages in rural Ohio. Family Health Services' specialty pharmacy services are powered by a partnership with AndHealth, a Columbus-based healthcare company that helps CHCs radically improve access and outcomes to specialty care. Ohioans can now fill their prescriptions directly through Family Health Services' pharmacy, where affordable medications are available to all patients under Family Health Service's sliding fee scale. 'There is an immense value in having specialty care and pharmacy services directly within our community,' said Jared Polick, Executive Director and CEO of Family Health Services. 'Residents of Darke County will now be able to receive care close to home and have the personal support of local clinical pharmacists and specialists. With this expansion, we're not just adding services, we're closing care gaps and removing barriers to health for our neighbors.' The updated Greenville facility now offers integrated medical, behavioral health, dental, rheumatology, dermatology, neurology, and pharmacy services under one roof – creating a true whole-person care environment that prioritizes convenience, coordination, and affordability. Addressing Ohio's Pharmacy Deserts and Improving Medication Access According to new data 1 released by the Ohio Board of Pharmacy, pharmacy closures have accelerated, and the state has lost hundreds of pharmacies over the past several years, leaving Ohioans with less than 2,000 retail pharmacies. Nearly 2 million Ohioans live in 'pharmacy deserts', or areas that lack convenient access to a pharmacy. 2 These access deserts disproportionately impact individuals in socially vulnerable communities, who face additional barriers to access and care, making the role of pharmacies located at CHCs even more central to improving community health in Ohio. AndHealth partners with Community Health Centers (CHCs) like Family Health Services to expand access to care by addressing pharmacy and care deserts. 'Ensuring our patients have access to affordable medications can only be accomplished when we reverse the trend of pharmacy consolidation and closure,' said Brenda Reitz, Family Health Services' Pharmacy Director. 'This pharmacy expansion allows us to support the community in new ways and ensures our neighbors needs can be met right here in Darke County.' Family Health Services' ribbon cutting will take place at its 5935 Meeker Rd location in Greenville at 4:00 P.M. on August 7 th with an open house to follow from 5:00 – 8:00 PM. The event is open to all, and guests are encouraged to RSVP by contacting Kalie Riffle at kriffle@ About Family Health Services Family Health Services is a Federally Qualified Health Center (FQHC) dedicated to building healthier lives through integrated, affordable care. With locations across Darke County, FHS provides comprehensive services – including medical, dental, behavioral health, specialty care, and pharmacy – to patients of all ages, regardless of insurance status or ability to pay. To learn more, visit About AndHealth AndHealth helps Community Health Centers (CHCs) radically improve access and outcomes for patients in specialty care and specialty pharmacy, while becoming an even larger and more clinically integrated part of our healthcare system. This Whole-Person Community Care Model provides everything CHCs need to deliver in-house specialty care and specialty pharmacy, built for the unique needs of our medically underserved populations. The model provides CHCs with more patients, more clinical capabilities, alignment with health systems, and sustainable reimbursement and funding that restores the integrity of the patient's medical home and their critical reimbursement model—both having shifted away from CHCs through external specialty referrals and contract pharmacies. In restoring this integrity, CHCs can tear down barriers to care and stretch scarce federal resources to reach more patients with comprehensive services that weren't possible before and that are desperately needed by patients. Headquartered in Columbus, Ohio, AndHealth is led by former CoverMyMeds co-founder and CEO Matt Scantland and the team that built Ohio's first healthcare technology unicorn, who have dedicated their lives to transformative innovation that improves access for patients. AndHealth is supported by key investors including the American Medical Association's innovation subsidiary, Francisco Partners, and the state of Ohio's economic development organization. To learn more, visit
Business Journals
4 minutes ago
- Business Journals
Stevens & Lee expands in New Jersey with acquisition of 8-lawyer firm
Stevens & Lee's latest acquisition marks its third expansion this summer, signaling an aggressive growth strategy for the Reading-based law firm.
Business Upturn
5 minutes ago
- Business Upturn
Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe
Concept Medical announces first patient enrollment in MAGICAL-SV IDE trial, expanding its Coronary Clinical Program across the U.S. and Europe. Business Wire India Concept Medical Inc. , a global pioneer in drug-delivery technologies, announced the enrollment of the first patient in the MAGICAL-SV (MAGIcTouch™ Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels) trial, a U.S. Investigational Device Exemption (IDE) study evaluating its MagicTouch™ sirolimus-coated balloon (SCB) for the treatment of small coronary vessels. This first U.S. enrollment follows the FDA's IDE approval of MagicTouch SCB, marking a major milestone in Concept Medical's mission to revolutionize coronary artery disease (CAD) treatment and expand its clinical program into the US and Europe. Dr. Samin Sharma enrolled the first patient at New York's Mount Sinai Hospital, Director of Interventional Cardiology, marking a crucial step in advancing treatment options for patients with small-vessel coronary artery disease. 'Today marks a great feat for us and for the MAGICAL-SV trial,' said Dr. Samin Sharma. 'My team at Mount Sinai is privileged to be the first to begin this study. This is a proud moment for all of us, especially knowing what the trial signifies and aims to achieve by evaluating MagicTouch as a potential alternative for treating small vessels in the U.S.' Concept Medical is now actively enrolling in three IDE trials concurrently in the U.S., across coronary and peripheral interventions, underscoring its commitment to bringing innovative therapies to patients worldwide. MAGICAL-SV is a prospective, multicenter, single-blind randomized trial (2:1 randomization) comparing Concept Medical's MagicTouch sirolimus-coated balloon to DES (Everolimus eluting stents [EES] or Zotarolimus eluting stents [ZES]) for the treatment of small coronary artery lesions. Randomization is stratified by study site and presence of medically-treated diabetes mellitus status. The trial will enroll 1,605 patients across the U.S. and Europe, to evaluate the primary endpoint of target lesion failure (TLF) at 12 months. An international team of renowned cardiologists, Dr. Martin B. Leon (USA) – Study Chair, with principal investigators (PI) Dr. Azeem Latib (USA), Dr. Ajay Kirtane (USA), and Prof. Antonio Colombo (Europe) will lead the MAGICAL-SV trial. Dr. Azeem Latib, a U.S. PI for MAGICAL-SV, noted, 'The first U.S. patient enrollment in the MAGICAL-SV study marks an exciting step forward in building robust evidence for SCB technology in the treatment of small-vessel coronary disease. As we explore metal-free PCI strategies, this study brings renewed hope for safer, more effective options for our patients.' Prof. Antonio Colombo, who leads the European arm, added, 'Starting small and going big! MAGICAL-SV represents an important step in building evidence for sirolimus-coated balloons.' This milestone embodies a 'leave nothing behind' philosophy in coronary interventions, treating arterial blockages without permanent implants and addressing the limitations of metallic stents in small vessels. Dr. Martin B. Leon, the Study Chair, emphasized evaluating a no-stent strategy through this trial: 'The initiation of the MAGICAL-SV trial marks an important step in evaluating sirolimus-coated balloon therapy for small coronary vessels. By addressing key limitations of stenting in this complex anatomy, the study aims to generate strong comparative data versus DES. The results could inform future treatment strategies in the U.S. and Europe, offering clinicians a potential alternative for managing small-vessel disease.' The pioneering MAGICAL-SV trial aims to yield strong clinical evidence for sirolimus-coated balloon therapy, supporting Pre-Market Approval (PMA) for MagicTouch SCB in small vessels and potentially redefining CAD treatment. Dr. Manish Doshi, Founder and MD of Concept Medical, said, "MAGICAL-SV marks another step in our mission to redefine vascular care. We're focused on delivering next-generation solutions, helping clinicians achieve better outcomes and give CAD patients a better quality of life." For media inquiries contact: [email protected] Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash
